CA2933867A1 - Micromolded or 3-d printed pulsatile release vaccine formulations - Google Patents

Micromolded or 3-d printed pulsatile release vaccine formulations Download PDF

Info

Publication number
CA2933867A1
CA2933867A1 CA2933867A CA2933867A CA2933867A1 CA 2933867 A1 CA2933867 A1 CA 2933867A1 CA 2933867 A CA2933867 A CA 2933867A CA 2933867 A CA2933867 A CA 2933867A CA 2933867 A1 CA2933867 A1 CA 2933867A1
Authority
CA
Canada
Prior art keywords
formulation
antigen
release
bsa
ipv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2933867A
Other languages
English (en)
French (fr)
Inventor
Ana Jaklenec
William Gates
Philip Andrew Welkhoff
Boris Nikolic
Lowell L. Wood
Robert S. Langer
Thanh Duc Nguyen
Stephany Yi Tzeng
James J. Norman
Kevin Mchugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Tokitae LLC
Original Assignee
Massachusetts Institute of Technology
Tokitae LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Tokitae LLC filed Critical Massachusetts Institute of Technology
Publication of CA2933867A1 publication Critical patent/CA2933867A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Shaping Of Tube Ends By Bending Or Straightening (AREA)
  • Micromachines (AREA)
CA2933867A 2013-12-16 2014-12-16 Micromolded or 3-d printed pulsatile release vaccine formulations Pending CA2933867A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361916555P 2013-12-16 2013-12-16
US61/916,555 2013-12-16
PCT/US2014/070664 WO2015095230A1 (en) 2013-12-16 2014-12-16 Micromolded or 3-d printed pulsatile release vaccine formulations

Publications (1)

Publication Number Publication Date
CA2933867A1 true CA2933867A1 (en) 2015-06-25

Family

ID=52396804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2933867A Pending CA2933867A1 (en) 2013-12-16 2014-12-16 Micromolded or 3-d printed pulsatile release vaccine formulations

Country Status (6)

Country Link
US (4) US10300136B2 (https=)
EP (2) EP3082852B1 (https=)
JP (4) JP2017507165A (https=)
AU (1) AU2014364930B2 (https=)
CA (1) CA2933867A1 (https=)
WO (1) WO2015095230A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014364930B2 (en) * 2013-12-16 2017-06-15 Massachusetts Institute Of Technology Micromolded or 3-D printed pulsatile release vaccine formulations
CA3254279A1 (en) 2015-06-03 2025-03-18 Triastek, Inc. PHARMACEUTICAL FORMS AND RELATED USES
US11395802B2 (en) * 2016-09-16 2022-07-26 Auburn University Biodegradable polymeric particles encapsulating an active agent, pharmaceutical compositions and uses thereof
US10150282B2 (en) 2016-10-14 2018-12-11 Xerox Corporation System and method for additive manufacture of chemical delivery devices using halftone screening
KR20190107712A (ko) 2017-01-26 2019-09-20 트리아스텍 인코포레이티드 특정 위장 부위에서의 제어 방출의 투여 형태
US10933579B2 (en) 2017-03-10 2021-03-02 Prellis Biologics, Inc. Methods and systems for printing biological material
US11085018B2 (en) 2017-03-10 2021-08-10 Prellis Biologics, Inc. Three-dimensional printed organs, devices, and matrices
EP3595515A4 (en) 2017-03-14 2020-12-30 University of Connecticut BIODEGRADABLE PRESSURE SENSOR
CN111032687A (zh) 2017-05-25 2020-04-17 普瑞利思生物制品公司 三维打印的器官、设备和基质
KR102626745B1 (ko) 2017-05-26 2024-01-17 인피니트 머티리얼 솔루션즈, 엘엘씨 수용성 중합체 조성물
WO2019055613A1 (en) * 2017-09-13 2019-03-21 Massachusetts Institute Of Technology COMPLEX GEOMETRY MICRODISPOSITIVES
CN116270513A (zh) 2018-01-09 2023-06-23 南京三迭纪医药科技有限公司 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
CN118320289A (zh) 2018-03-05 2024-07-12 康涅狄格大学 用于经皮和脉冲药物/疫苗递送的核壳微针平台及其制造方法
CA3102755A1 (en) * 2018-06-29 2020-01-02 The Doshisha Formulation containing emricasan
WO2020027035A1 (ja) * 2018-07-30 2020-02-06 三菱ケミカル株式会社 熱溶融型積層造形用材料
WO2020028436A1 (en) * 2018-07-31 2020-02-06 Prellis Biologics, Inc. Optically-induced auto-encapsulation
US12397052B2 (en) * 2018-08-20 2025-08-26 Institute Of Process Engineering, Chinese Academy Of Sciences Microcapsule-based vaccine
US11826495B2 (en) 2019-03-01 2023-11-28 University Of Connecticut Biodegradable piezoelectric ultrasonic transducer system
US11678989B2 (en) 2019-03-01 2023-06-20 University Of Connecticut Biodegradable piezoelectric nanofiber scaffold for bone or tissue regeneration
CN110420324B (zh) * 2019-08-01 2022-07-12 临沂大学 含兔葡萄球菌抗原的免疫原性组合物及其制备方法和应用
US11745001B2 (en) 2020-03-10 2023-09-05 University Of Connecticut Therapeutic bandage
US12371581B2 (en) 2020-03-25 2025-07-29 Infinite Material Solutions, Llc High performance water soluble polymer compositions
JP2023522244A (ja) * 2020-04-20 2023-05-29 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 乾燥製剤を生成する方法
JP7776145B2 (ja) * 2020-05-13 2025-11-26 マサチューセッツ インスティテュート オブ テクノロジー ポリマーマイクロデバイスの組成物およびがん免疫療法におけるその使用
US12491290B2 (en) 2020-06-08 2025-12-09 University Of Connecticut Biodegradable piezoelectric composite materials
CN112370531B (zh) * 2020-11-18 2022-09-23 金宇保灵生物药品有限公司 一种犬瘟热、犬细小、犬腺病毒、犬副流感四联活疫苗耐热保护剂及其制备方法和应用
WO2022192361A2 (en) * 2021-03-09 2022-09-15 Board Of Regents Of The University Of Nebraska Microparticle compositions and methods use thereof
EP4358944A4 (en) * 2021-06-21 2025-03-12 William Marsh Rice University HIGH-YIELD PREPARATION OF PULSATILE-RELEASE MICROPARTICLES
CN113521263A (zh) * 2021-08-03 2021-10-22 苏州大学 一种3d打印的肿瘤疫苗组合物及其制备方法与应用
WO2024026039A2 (en) * 2022-07-27 2024-02-01 Board Of Regents, The University Of Texas System Multi-channeled and guided inner controlling (magic) printheads
WO2024215759A2 (en) * 2023-04-11 2024-10-17 The Regents Of The University Of California Biodegradable scaffolds for enhancing vaccine efficacy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US5490962A (en) 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
WO1995011010A1 (en) 1993-10-22 1995-04-27 Genentech, Inc. Methods and compositions for microencapsulation of antigens for use as vaccines
EP1009386B1 (en) 1997-08-29 2005-08-31 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
CA2386151A1 (en) 1999-10-12 2001-04-19 Marc Madou Reactive polymeric valve, dispensing devices and methods using same
DE60027458T2 (de) 1999-12-10 2007-07-05 Massachusetts Institute Of Technology, Cambridge Mikrochip-arzneistoffverabreichungssysteme und herstellungsverfahren
US6565532B1 (en) 2000-07-12 2003-05-20 The Procter & Gamble Company Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
ES2310201T3 (es) 2001-02-13 2009-01-01 Government Of The United States Of America, As Represented By The Secretary Of The Army Vacuna para inmunizacion transcutanea contra la diarrea de los viajeros.
CA2461616A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
US7122143B2 (en) * 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
DE60323482D1 (de) * 2002-05-06 2008-10-23 Massachusetts Inst Technology Diffusionskontrollierte arzneiform sowie herstellungsmethode mittels dreidimensionalem drucken
JP2007516238A (ja) 2003-11-12 2007-06-21 ザ ジェネラル ホスピタル コーポレーション 可変性外観組織マーキング
US9040090B2 (en) 2003-12-19 2015-05-26 The University Of North Carolina At Chapel Hill Isolated and fixed micro and nano structures and methods thereof
CA2551644C (en) 2003-12-24 2014-03-04 Cerus Corporation Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of usethereof
CN1921884B (zh) 2003-12-24 2012-02-08 塞鲁斯公司 重组核酸分子,表达盒和细菌,及其使用方法
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2006121819A1 (en) 2005-05-06 2006-11-16 Board Of Regents, The University Of Texas System Methods for fabricating nano and microparticles for drug delivery
CA2613474A1 (en) 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
CN101227940A (zh) 2005-07-25 2008-07-23 纳米技术维多利亚有限公司 微阵列装置
EP1908196B1 (en) 2005-07-28 2012-11-07 Mformation Technologies, Inc. System and method for service quality management for wireless devices
US20080026040A1 (en) * 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
US8349326B2 (en) 2007-02-20 2013-01-08 Tufts University Methods and systems for multi-antibody therapies
CA2700356C (en) 2007-09-27 2013-07-09 Akina, Inc. Sol-gel phase-reversible hydrogel templates and uses thereof
EP2630966B1 (en) 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
JP2011514337A (ja) 2008-02-25 2011-05-06 ノババックス，インコーポレイテッド 糖ガラス化ウィルス様粒子（ｖｌｐ）
US10463608B2 (en) 2008-09-29 2019-11-05 The Corporation Of Mercer University Microneedle-based transdermal delivery system and method of making same
CA2769102C (en) 2009-07-31 2017-09-19 3M Innovative Properties Company Hollow microneedle arrays
US10046109B2 (en) 2009-08-12 2018-08-14 Progenity, Inc. Drug delivery device with compressible drug reservoir
WO2011156641A2 (en) 2010-06-09 2011-12-15 Kaspar Roger L Microneedle arrays for active agent delivery
AU2011336413B2 (en) * 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
US20130046182A1 (en) 2011-08-16 2013-02-21 Elwha LLC, a limited liability company of the State of Delaware Devices and Methods for Recording Information on a Subject's Body
CN103251941A (zh) * 2012-02-16 2013-08-21 海南大学 动物病毒性疫苗脉冲释放系统、其制备方法及用途
BR112014029760A2 (pt) 2012-05-30 2017-06-27 Univ California dispositivos de distribuição de agente bioativo e métodos para fazer e usar os mesmos
US20140200508A1 (en) 2012-06-29 2014-07-17 Isaac D. Cohen Microneedles Comprising One Or More Cosmetic Ingredients
TWI554289B (zh) 2012-06-29 2016-10-21 國立成功大學 鑲嵌式經皮藥物釋放貼片及其製造方法
ITTO20130284A1 (it) 2013-04-09 2014-10-10 Fond Istituto Italiano Di Tecnologia Procedimento per la produzione di microparticelle polimeriche sagomate
EP3021930B1 (en) 2013-07-16 2020-10-07 3M Innovative Properties Company Hollow microneedle with beveled tip
AU2014364930B2 (en) * 2013-12-16 2017-06-15 Massachusetts Institute Of Technology Micromolded or 3-D printed pulsatile release vaccine formulations

Also Published As

Publication number Publication date
EP3763383A1 (en) 2021-01-13
JP7682019B2 (ja) 2025-05-23
US20190328871A1 (en) 2019-10-31
JP2023075311A (ja) 2023-05-30
US20150165020A1 (en) 2015-06-18
JP2021120413A (ja) 2021-08-19
JP2020055818A (ja) 2020-04-09
US10300136B2 (en) 2019-05-28
EP3082852A1 (en) 2016-10-26
AU2014364930B2 (en) 2017-06-15
US20210205444A1 (en) 2021-07-08
US20240181047A1 (en) 2024-06-06
US11975069B2 (en) 2024-05-07
WO2015095230A1 (en) 2015-06-25
AU2014364930A1 (en) 2016-07-14
JP2017507165A (ja) 2017-03-16
US10960073B2 (en) 2021-03-30
EP3082852B1 (en) 2020-06-17

Similar Documents

Publication Publication Date Title
US20240181047A1 (en) Micromolded or 3-d printed pulsatile release vaccine formulations
US20210290921A1 (en) Microdevices with complex geometries
Hajavi et al. Optimization of PLGA formulation containing protein or peptide‐based antigen: recent advances
AU2009290656A1 (en) Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
WO2011018504A2 (en) Immunomodulatory compositions comprising a polymer matrix and an oil phase
Sinsinbar et al. Amphiphilic block copolymer nanostructures as a tunable delivery platform: perspective and framework for the future drug product development
Hou et al. Up-to-date vaccine delivery systems: robust immunity elicited by multifarious nanomaterials upon administration through diverse routes
Prashant et al. Nanoparticle based tailoring of adjuvant function: the role in vaccine development
Kaur et al. Polymer particulates in drug delivery
Diesner et al. Use of lectin-functionalized particles for oral immunotherapy
US20110163469A1 (en) High-throughput fabrication of microparticles
Takada Microfabrication derived DDS: From batch to individual production
Nechaeva Development of oral microencapsulated forms for delivering viral vaccines
Paul et al. A review on microspheres as controlled release drug delivery
Schiller Scalable processes to manufacture nanoparticulate dosage forms for oral vaccination
Pal et al. Drug Delivery to the Immune System: Immunotherapies and Vaccines
Wang et al. Microspheres and microcapsules for protein drug delivery
WEI et al. Research progress of microsphere formulations with narrow size distribution
Lin et al. The preparation and characteristic of poly (lactide co–glycolide) microspheres as novel antigen delivery systems
Lahane et al. Role of Nanoparticle Formulation for the Combination Delivery of Multiple Antigens
Akiko Kiriyama Availability of polymeric nanoparticles for specific enhanced and targeted drug delivery
Sajeesh et al. Micro-and Nanoparticles: Protein and Peptide Oral Delivery
Kaur et al. Particulates: Drug Delivery
Guan Fabrication of polymeric microparticles for drug delivery

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160614

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251212

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128